Progentos Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $68.6M

  • Investors
  • 8

Progentos Therapeutics General Information

Description

Developer of a regenerative medicine platform designed to stimulate the body's own repair mechanisms to restore myelin in multiple sclerosis. The company offers novel small-molecule compounds that activate oligodendrocyte progenitor cells, enabling patients with chronic diseases, such as multiple sclerosis, to regain lost neurological function and improve their quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 763 Concord Avenue
  • Cambridge, MA 02138
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 763 Concord Avenue
  • Cambridge, MA 02138
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Progentos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 14-May-2024 $68.6M Completed Pre-Clinical Trials
To view Progentos Therapeutics’s complete valuation and funding history, request access »

Progentos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-4
Series A-3
Series A-2 16,250,000 $0.000100 8% $0.8 $0.8 1x $0.8 13.09%
Series A-1 5,602,736 $0.000100 8% $0.64 $0.64 1x $0.64 4.51%
To view Progentos Therapeutics’s complete cap table history, request access »

Progentos Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a regenerative medicine platform designed to stimulate the body's own repair mechanisms to restore myelin i
Drug Discovery
Cambridge, MA
7 As of 2026

Leuven, Belgium
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Progentos Therapeutics Competitors (19)

One of Progentos Therapeutics’s 19 competitors is Rewind Therapeutics, a Venture Capital-Backed company based in Leuven, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rewind Therapeutics Venture Capital-Backed Leuven, Belgium
AnTolRx Formerly VC-backed Cambridge, MA
Sudo Biosciences Venture Capital-Backed Carmel, IN
Baliopharm Venture Capital-Backed Basel, Switzerland
Prevail Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 19 competitors. Get the full list »

Progentos Therapeutics Patents

Progentos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026516101-A Heterocyclic compounds and their uses Pending 09-May-2023
AU-2024269869-A1 Heterocyclic compounds and uses thereof Pending 09-May-2023
EP-4709725-A1 Heterocyclic compounds and uses thereof Pending 09-May-2023
WO-2024233642-A1 Heterocyclic compounds and uses thereof Inactive 09-May-2023
AU-2022379973-A1 Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof Pending 08-Nov-2021 C07D471/04
To view Progentos Therapeutics’s complete patent history, request access »

Progentos Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Progentos Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Dolby Family Ventures Venture Capital Minority
Forbion Venture Capital Minority
Longwood Fund Management Venture Capital Minority
Mission BioCapital Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Progentos Therapeutics FAQs

  • When was Progentos Therapeutics founded?

    Progentos Therapeutics was founded in 2023.

  • Where is Progentos Therapeutics headquartered?

    Progentos Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Progentos Therapeutics?

    Progentos Therapeutics has 7 total employees.

  • What industry is Progentos Therapeutics in?

    Progentos Therapeutics’s primary industry is Drug Discovery.

  • Is Progentos Therapeutics a private or public company?

    Progentos Therapeutics is a Private company.

  • What is the current valuation of Progentos Therapeutics?

    The current valuation of Progentos Therapeutics is .

  • What is Progentos Therapeutics’s current revenue?

    The current revenue for Progentos Therapeutics is .

  • How much funding has Progentos Therapeutics raised over time?

    Progentos Therapeutics has raised $68.6M.

  • Who are Progentos Therapeutics’s investors?

    Alta Partners, Dolby Family Ventures, Forbion, Longwood Fund Management, and Mission BioCapital are 5 of 8 investors who have invested in Progentos Therapeutics.

  • Who are Progentos Therapeutics’s competitors?

    Rewind Therapeutics, AnTolRx, Sudo Biosciences, Baliopharm, and Prevail Therapeutics are some of the 19 competitors of Progentos Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process